



Published in final edited form as:

J Affect Disord. 2022 January 15; 297: 671–678. doi:10.1016/j.jad.2021.10.025.

Prefrontal Transcranial Magnetic Stimulation for Depression in US Military Veterans – A Naturalistic Cohort Study in the Veterans Health Administration

Michelle R Madore¹, F Andrew Kozel², Leanne M Williams¹, L Chauncey Green¹, Mark S George³, Paul E Holtzheimer⁴, Jerome A Yesavage¹, Noah S Philip⁵

¹ Mental Illness Research, Education, and Clinical Center, VA Palo Alto Healthcare System, Palo Alto, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, CA, USA.

² Department of Behavioral Sciences and Social Medicine, Florida State University, Tallahassee, FL, USA; Mental Health and Behavioral Sciences, James A. Haley Veterans' Administration Hospital and Clinics, Tampa, FL, USA; Department of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.

³ Ralph H. Johnson VA Medical Center, Charleston, SC, USA; Brain Stimulation Laboratory, Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.

⁴ National Center for PTSD, White River Junction, VT, United States; Geisel School of Medicine at Dartmouth, Hanover, NH, USA.

⁵ VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Healthcare System, Providence, RI, USA; Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA.

Abstract

noah_philip@brown.edu.

Author statement

Drs. Madore, Kozel and Philip designed the study and conducted the initial analysis, assisted by Mr. Green; Drs. Yesavage and George were involved in the formation of the parent program. Drs. Holtzheimer and Williams contributed to the interpretation of the results. All authors materially participated in the research and manuscript preparation; all authors have approved the final submission. This manuscript is not submitted to another journal, and that all relevant support and conflicts of interest are described in the submission.

CONFLICT OF INTEREST STATEMENTS

In the last three years: LMW declares fees as Advisory Board Member for One Mind Psyberguide and as External Advisory Committee of the Laureate Institute for Brain Research, and US Pants. App. 10/034,645 and 15/820,338: Systems and methods for detecting complex networks in MRI image data, unrelated to this study. MSG has received equipment support for research from Magstim and Nexstim, and has conducted research at MUSC funded by Brainsway. PEH receives consulting fees from Abbott and royalties from UpToDate and Oxford University Press. NSP has received equipment support (through VA clinical trial contracts) from Wave Neuro. Other authors have no biomedical conflicts of interest to disclose.

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The data that support the findings of this study may be available from the corresponding author upon reasonable request, subject to Department of Veterans Affairs policies.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Background: Repetitive transcranial magnetic stimulation (TMS) is an evidence-based treatment for pharmacoresistant major depressive disorder (MDD), however, the evidence in veterans has been mixed. To this end, VA implemented a nationwide TMS program that included evaluating clinical outcomes within a naturalistic design. TMS was hypothesized to be safe and provide clinically meaningful reductions in MDD and posttraumatic stress disorder (PTSD) symptoms.

Methods: Inclusion criteria were MDD diagnosis and standard clinical TMS eligibility. Of the 770 patients enrolled between October 2017 and March 2020, 68.4% (n=521) met threshold-level PTSD symptom criteria. Treatments generally used standard parameters (e.g., left dorsolateral prefrontal cortex, 120% motor threshold, 10Hz, 3000 pulses/treatment). Adequate dose was operationally defined as 30 sessions. MDD and PTSD symptoms were measured using the 9-item patient health questionnaire (PHQ-9) and PTSD checklist for DSM-5 (PCL-5), respectively.

Results: Of the 770 who received at least one session, TMS was associated with clinically meaningful (Cohen's $d > 1.0$) and statistically significant (all $p < .001$) reductions in MDD and PTSD. Of the 340 veterans who received an adequate dose, MDD response and remission rates were 41.4% and 20%, respectively. In veterans with comorbid PTSD, 65.3% demonstrated clinically meaningful reduction and 46.1% no longer met PTSD threshold criteria after TMS. Side effects were consistent with the known safety profile of TMS.

Limitations: Include those inherent to retrospective observational cohort study in Veterans.

Conclusions: These multisite, large-scale data supports the effectiveness and safety of TMS for veterans with MDD and PTSD using standard clinical approaches.

Keywords

transcranial magnetic stimulation; major depressive disorder; posttraumatic stress disorder; Veterans

INTRODUCTION

Major depressive disorder (MDD) affects patients across the globe as a leading cause of disability (Friedrich, 2017), is a major contributor to suicide, and a risk factor for poor medical outcomes. Current treatments rely upon medications and psychotherapy, with limited options for the approximately one third of patients who do not respond (Rush AJ, et al., 2006). Other options typically include electroconvulsive therapy, which is limited in use due to risks of anesthesia and short-term memory impairment (Sackeim 2017). While there are investigations of emerging novel agents (e.g., (es)ketamine, psilocybin, etc.) (Davis et al., 2020; McIntyre, et al., 2021) there are concerns about abuse potential and long-term effectiveness.

Repetitive transcranial magnetic stimulation (rTMS, hereafter TMS), an evidence-based treatment for pharmacoresistant MDD, has been cleared by the US Food and Drug Administration since 2008 (O'Reardon et al., 2007; George, et al., 2010). Although there is a rare risk of seizure during stimulation, TMS has a favorable safety profile without systemic side effects (weight gain, diabetes, etc.). Data has now emerged supporting TMS across psychiatric disorders, including obsessive-compulsive disorder, smoking cessation,

posttraumatic stress disorder (PTSD), and schizophrenia (reviewed in (George 2019; Cosmo et al., 2021).

One patient population of interest is US military veterans. Several factors related to Veteran care are relevant to TMS. These patients have elevated rates of medical and psychiatric comorbidity (Agha et al., 2000) as well as suicide risk (Dept. of Veterans Affairs, 2016). Given these challenges to treatment, veterans stand to benefit further from non-pharmacological treatments that may also reduce suicidality. Furthermore, TMS access and delivery are likely to be different in the VA, as private insurance is not involved in eligibility determination. Interestingly, unlike in the general population, the efficacy data on TMS in Veterans has been mixed. Unlike other TMS efficacy studies (O'Reardon et al., 2007; George et al., 2010), a recent controlled trial in veterans by Yesavage et al., (2018) found that active TMS did not separate from sham, and comorbid PTSD was associated with poorer outcomes. Interestingly, this study yielded high remission rates (defined as obtaining scores below threshold values on standardized rating scales) in both active (40.7%) and sham (37.4%) groups. While the reason for these results remains debated in the field, this study had strict monitoring of medication usage that reminded participants to take their daily psychiatric medications. This monitoring likely caused some participants to begin regularly taking their medication which resulted in effectively starting the medication and the TMS (active and sham) simultaneously. To this point, two other studies that failed to differentiate active from sham (Herwig, Fallgatter, Höppner et al., 2007; Brunelin, Jalenques, Trojak et al., 2014) initiated antidepressants at the same time as TMS. Despite findings from Yesavage et al., other studies have consistently indicated efficacy of TMS for Veterans, including those with comorbid MDD and PTSD (Karsen et al., 2014; Kozel et al., 2019; Philip et al., 2019). In addition, an analysis of clinical outcomes of TMS for depressed veterans (n=118; with nominal overlap with the current report) found PTSD did not impact MDD response or remission rates (Hernandez et al., 2020). Furthermore, a recent meta-analysis supports the efficacy of TMS for PTSD (Kan et al., et al., 2020).

Within the context of these mixed data, and to address the health needs of veterans, the Veterans Health Administration (VA) instituted a nationwide multisite TMS program, informed by prior positive controlled trials (O'Reardon et al., 2007; George, et al., 2010), and naturalistic studies (Carpenter et al., 2012). This program was designed to provide evidenced-based TMS for MDD to veterans and evaluate clinical effectiveness and safety. This report represents the first outcomes from the program. We hypothesized TMS would be safe and effective for MDD and comorbid PTSD. We also assessed patients who received an adequate TMS dose, operationalized as at least 30 daily sessions, and compared to the entire cohort.

METHODS

Project Organization

The VA Palo Alto Healthcare System Mental Illness Research Education and Clinical Center (MIRECC) served as the coordinating site for this retrospective observational cohort study. The VA Palo Alto/Stanford Institutional Review Board approved associated procedures as quality improvement and data was gathered via VA REDCap. The "VA TMS Pilot Program"

distributed devices, identified existing TMS clinics, and provided high quality training (Carrico et al., 2020). The VA has a strong track record of implementing evidence-based care (e.g., Eftekhari et al., 2013), which can be harnessed to disseminate novel treatments and provide infrastructure for important research questions (Williams et al., 2021).

Referral and Treatment Information

Patients were referred by their primary mental healthcare provider, and determined to be eligible if they met TMS indication criteria (e.g., failure of >1 antidepressant in the current depressive episode). The recommendation was for patients to have a MDD diagnosis, which could be comorbid with other diagnoses such as PTSD. Standard contraindications were utilized (e.g., seizures, intracranial metal, etc.). A TMS-credentialed VA physician performed an initial evaluation and verified other treatments (e.g., medication, psychotherapy, etc.) were unchanged six weeks prior to stimulation. No medication was absolutely contraindicated, and treatment continued unchanged throughout TMS (the impact of medications will be the topic of a future report). Clinical factors, such as adherence or substance use, were assessed daily following standard clinical care.

Devices and Parameters

TMS devices included the Magstim Super Rapid², Horizon Lite, or Horizon Performance device (Wales, UK); some sites used others purchased outside the program (e.g., Neuronetics, Malvern PA, USA; MagVenture, Farum, Denmark; Brainsway, Jerusalem, Israel). Motor threshold determination was performed prior to stimulation and defined as the amount of energy applied to the motor cortex to elicit movement in the contralateral fingers (typically abductor pollicis brevis) 50% of the time. The TMS target was the left dorsolateral prefrontal cortex (DLPFC), located using the Beam/F3 method (Beam, et al., 2009). Sites were advised to follow FDA guidelines, and generally administered high frequency stimulation, e.g., daily TMS delivered at 10 Hz to the left DLPFC at 120% of motor threshold for up to 30 sessions followed by a six-session taper. Based on clinical judgement, parameters could be modified when following an evidence-based off-label approach, which was reported in the REDCap database (Table 2).

Measures and Statistical Analyses

Standardized self-report rating scales were selected based on those used in clinical (non-research) settings to provide adequate information about symptom severity while minimizing burden. Primary outcomes were changes in MDD and PTSD symptom severity; subsequent reports will include other assessments. MDD and PTSD were measured using the 9-item patient health questionnaire (PHQ-9; (Kroenke et al., 2001)) and PTSD symptom checklist for DSM5 (PCL-5; (Weathers et al., 2013a)), respectively. Outcomes of interest included mean changes, dichotomous/categorical outcomes describing MDD clinical response (>50% reduction) and remission (score<5) on the PHQ9, and PTSD outcomes of clinically meaningful reduction (>10 points) and those no longer meeting threshold severity criteria for probable PTSD (operationally defined as score <33 on the PCL-5 (following (Weathers et al., (2013a))). Outcomes were analyzed using paired-sample t-tests for continuous outcomes, descriptive statistics for categorical outcomes, and analysis of variance to assess symptom changes over time. Patients were excluded from relevant

analyses if baseline scores were less than remission (MDD) or clinically relevant PTSD severity (PTSD). Missing data were reconciled via site query, with individual sites reporting dropouts and associated reasons. Effect sizes (Cohen's d , (1988)) and confidence intervals were generated for continuous outcomes. Sensitivity analyses were performed on several key areas of clinical interest, including definition of adequate dose and TMS parameters. Safety was assessed via spontaneous patient report recorded in the database and site queries.

This report includes all veterans that received TMS at 27 VA sites from October 2017 until March 2020 (i.e., pre-COVID-19). Results were analyzed using two approaches; first, following modified “intent-to-treat” principles, where patients who received baseline assessments and >1 TMS session were included in the “entire group” analyses. This was followed by analyses focused on the “adequate dose group” who received an adequate dose of TMS, operationalized as at least 30 sessions (i.e., a single daily session for six weeks).

RESULTS

PATIENT CHARACTERISTICS

Seven hundred seventy (n=770) patients were in the entire group and 340 received an adequate dose. Demographics were consistent with veterans (i.e., majority white and male), yet many races, ethnicities, and genders were represented (Table 1). Military service encompassed multiple eras (e.g., Vietnam, Gulf War, Operation Iraqi and Enduring Freedom, etc.). There were no meaningful site differences in baseline symptom severity (all $p>.1$). For this examination, patients were followed for the duration of TMS (i.e., 6–8 weeks). The majority of patients received 10 Hz TMS to the left DLPFC (n=595; 69.8%), with modest representation of other approaches (Table 2).

CLINICAL OUTCOMES

MDD Symptom Change with TMS—When considering the entire cohort (i.e., baseline assessment and >1 TMS session), the sample included 770 veterans, and 126 (16.4%) were classified as dropping out (see below). Mean (SD) pretreatment PHQ9 score was 18.14 (5.18), indicating moderately severe MDD. After treatment, PHQ9 score was reduced to 11.02 (7.11), which was statistically significant ($t(542)=25.996$, $p<.001$). PHQ9 reduction was clinically meaningful at 7.12 (6.38) points (Figure 1A) and reflected a large effect size (Cohen's $d=1.12$ (95% CI 1.04–1.21). Categorical outcomes included clinical response in 235 (30.5%) and remission in 118 (15.3%) patients. Regression co-varying for the presence of PTSD indicated no impact on PHQ9 change ($F(1,539)=0.065$, $p=0.799$).

Regarding PTSD outcomes in the entire cohort, 522 (67.8%) had threshold-level PTSD symptom severity at baseline. Pretreatment mean (SD) PCL-5 score was 54.22 (12.11), indicating moderate PTSD severity. After TMS, PCL-5 was reduced to 34.76 (19.81), which was statistically significant ($t(364)=20.70$, $p<.001$), and clinically meaningful with a reduction of 18.49 (17.05) points. This change also reflected a large effect size (Cohen's $d=1.11$ (95% CI 0.97–1.25). After TMS, 300 (57.4%) patients demonstrated a clinically meaningful reduction and 312 (59.8%) no longer met threshold criteria for probable PTSD

– all statistically significant ($p < 0.01$). Changes in MDD and PTSD symptoms were highly correlated ($r = 0.521$, $p < .001$).

When considering MDD outcomes in patients who received an adequate TMS dose, 340 veterans remained (Figure 1B). Pretreatment PHQ9 scores were 18.34 (5.24); after treatment, PHQ9 scores were 11.29 (7.08), which was statistically significant ($t(339) = 21.06$, $p < .001$). PHQ9 scores improved 7.12 (6.21) points, which was clinically meaningful and reflected a large effect size (Cohen's $d = 1.15$ (95% CI 1.00–1.30)). Categorical outcomes included response in 149 (41.4%) and remission in 72 (20.0%) patients.

Regarding PTSD outcomes in patients who received an adequate dose, 245 (70%) had threshold level PTSD symptom severity at baseline. Pretreatment PCL-5 score was 52.67 (11.91), indicating moderate severity. After TMS, the mean PCL-5 score was 33.74 (18.87), which was statistically different ($t(230) = 17.85$, $p < .001$). Improvements were clinically meaningful, with an 18.95 (16.14)-point reduction that reflected a large effect size (Cohen's $d = 1.20$ (95% CI 1.01–1.38)). After TMS, 160 (65.3%) demonstrated a clinically meaningful reduction and 113 (46.1%) no longer met PTSD criteria. MDD and PTSD changes were highly correlated ($r = 0.623$, $p < .001$).

We performed several sensitivity analyses to explore important clinical questions. First, we found our results were not sensitive to the definition of adequate dose (i.e., 20 vs. 30 sessions). We also explored whether FDA-cleared parameters might yield superior outcomes on MDD or PTSD, and found no significant differences (Supplement 1).

Comparing MDD outcomes in veterans with probable PTSD versus non-PTSD

—Because prior reports indicated mixed MDD outcomes in veterans with comorbid PTSD treated with TMS, we compared outcomes in veterans with versus without PTSD. When evaluating the entire cohort, MDD improved over time ($F(1,547) = 207.654$, $p < 0.001$) and the presence of clinically significant PTSD symptoms did not impact decreases in depressive symptoms ($F(1,547) = 0.030$, $p > 0.862$). Post-hoc analyses revealed individuals with PCL-5 scores > 33 had higher PHQ-9 scores (i.e., PHQ9 scores of 19.64 (4.46) versus 14.48 (5.80) for those with versus those without threshold-level symptom severity; $F(1,659) = 159.10$, $p < 0.001$) (Figure 2A). While PTSD did not impact the magnitude of reduction in depressive symptoms, MDD response rates were lower in PTSD patients (17.5% versus 26.7% for response rates in PTSD and non-PTSD, respectively; $\chi^2(1, N = 558) = 11.35$, $p = .001$). Remission rates were statistically poorer in PTSD patients, although rates were nearly identical (11.2% versus 11.6% in PTSD and non-PTSD, respectively; $\chi^2(1, N = 541) = 27.18$, $p < .001$).

When comparing PTSD versus non-PTSD patients who received an adequate TMS dose, a similar pattern emerged; depressive symptoms improved over time ($F(1,373) = 140.20$, $p < 0.010$) and PTSD did not impact the magnitude of depression improvement ($F(1,373) = 0.405$, $p > 0.525$). Post-hoc analyses again indicated PTSD patients had higher baseline PHQ-9 scores (i.e., 19.70 (4.45) and 15.21 (5.57) for those with and without PTSD, respectively; $F(1,348) = 63.86$, $p < .001$) (Figure 2B). Response rates for depression were lower in PTSD patients (26.6% versus 17.8% in PTSD and non-PTSD, respectively;

$\chi^2(1, N=374)=12.96, p<.001$). Remission rates were statistically lower in PTSD patients, although these rates were nearly identical (10.4% versus 11.0% for remission in PTSD and non-PTSD, respectively; $\chi^2(1, N=370)=17.35, p<.001$).

SAFETY

TMS was safe, with significant adverse outcomes occurring in <1% of patients. Six reported exacerbations of significant underlying psychiatric symptoms during TMS, largely related to worsening depression or anxiety. Two had significant medical events unrelated to TMS. One veteran had a seizure while being treated with an H-coil system and treatment was discontinued. There were no contraindications or risk factors noted in the pretreatment evaluation of this patient. There were no reports of treatment-emergent mania. A total of $n=126$ (16.4%) of the entire sample dropped out for any reason.

DISCUSSION

This report describes a multisite retrospective cohort study of TMS for veterans with MDD. The majority of patients reported comorbid MDD and PTSD, and pretreatment symptom severity was at least moderate. TMS resulted in statistically significant and clinically meaningful symptom reduction in all measured domains. TMS was safe, with side effects (including one seizure) consistent with its known safety profile, and retention was high. To our knowledge, this is the largest study of TMS in veterans to date, and clearly demonstrates effectiveness.

MDD improvements were associated with large effect sizes (all Cohen's d 's >1.0), regardless of how one examined the data. When considering categorical outcomes, those who received an adequate dose (i.e., >30 sessions), MDD response rates were 41.4% and the remission rate was 20.0%. As expected, those who did not receive an adequate dose had lower response and remission rates (30.5% and 15.3%). These were slightly lower than prior naturalistic/uncontrolled studies of TMS for MDD, which likely reflects psychiatric and medical comorbidities in veterans (15–16). For example, Carpenter et al (2021), reported response and remission rates of 56.4% and 28.7% in non-Veterans, and a recent a TMS registry report (non-Veterans) found response and remission rates up to 72% and 37%. For reference, all of these outcomes appear superior to acute remission rates in the STAR*D study, when considering comparably resistant patients (Sackeim 2016)).

Conversely, an earlier report of clinical outcomes of TMS for MDD in veterans found a similar response and remission rate (45% and 20% respectively)(Kozel et al, 2017). In another study comparing standard TMS versus theta burst TMS for MDD (Blumberger et al., 2018), response and remission rates were 49% and 32%. Interestingly, remission rates observed in this cohort study were lower than in the controlled trial of TMS in veterans (20% here versus 37–40% in Yesavage et al (2018)); the reason behind this discrepancy can only remain speculative.

These data demonstrate the importance of delivering an entire TMS treatment series. While overall magnitude of improvement (~7 point reduction on the PHQ9; $d \approx 1.1$) was comparable, response and remission rates were superior in patients that received >30 TMS

sessions; this is not explained by differences in baseline severity. Future studies will need to evaluate the relationship between the number of sessions required for optimal outcomes; however, since remission is the goal of antidepressant treatment, patients can be empirically recommended to receive six weeks of TMS.

Our cohort is notable as the majority reported significant comorbid PTSD. While some overlap is expected due to the nature of the rating scales (e.g., depressive questions and the mood/cognitive component of the PCL-5), over two thirds reported “threshold” level of PTSD severity. While structured clinical interviews (e.g., the Clinician Administered PTSD Scale (Weathers et al., 2013b)) were not performed, this comorbidity rate is high; as a point of reference, approximately 50% of patients in prior studies reported comorbid PTSD (Yesavage et al., 2018, Hernandez et al., 2020). In our estimation, this indicates the kind of VA patients most likely to be referred to TMS after prior treatment failures.

Observed PTSD outcomes are comparable to other studies of TMS for PTSD. PTSD improvements were statistically significant and clinically meaningful; of those patients with threshold-level PTSD symptoms at baseline, a near majority no longer met this criterion after TMS. This rate is similar to findings in smaller unblinded studies (e.g., Carpenter et al., 2018). In short, this study clearly demonstrates the effectiveness of TMS to reduce PTSD with comorbid MDD, and can be recommended for these patients.

Interestingly, the presence (or absence) of threshold-level PTSD symptoms did not impact the magnitude of observed MDD improvement (i.e., ~7 points on the PHQ9). Yet, MDD response and remission rates in patients with comorbid PTSD were lower than those without PTSD. This appears to be related to the higher level of baseline MDD symptoms in those with PTSD, which would require a greater magnitude of symptom reduction to achieve response and remission. Further defining the relationship between PTSD and MDD domains in clinical care – such as whether one can be used to predict the other, or whether they can be considered independent - is an important area of further inquiry.

Perhaps remarkably, PTSD improved with 10Hz stimulation to the left DLPFC, the traditional target for MDD. Whether there is an ideal TMS site for PTSD has received considerable attention, with studies using left-sided stimulation (Yesavage et al., 2018; Carpenter et al., 2018; Philip et al., 2016), right-sided stimulation (Kozel et al., 2019; Philip et al., 2019; Watts et al., 2012; Kozel et al., 2018), a mixture thereof (; Ahmadizadeh & Rezai 2018; Leong K et al., 2020; Boggio et al., 2010) or broader stimulation (Isserles et al., 2013; Isserles et al., 2021); clear superiority of any approach has yet to be demonstrated (e.g., Philip et al., 2021). These results raise important questions as to whether there is an ideal TMS approach best suited for PTSD reduction. While future analyses of this database will compare various parameters, these results indicate left-sided stimulation can improve PTSD.

Limitations of this work are those inherent to cohort studies. Primarily, stimulation was unblinded and so the impact of placebo or nonspecific effects cannot be assessed. Outcomes relied heavily on self-reported clinical scales, and future examination of other scales and functional outcomes is anticipated. Patients were engaged in concurrent clinical care,

and so we cannot identify the unique contribution of stimulation, and the effect of visit attendance may have induced an effect. Antidepressant resistance (i.e., how many failed prior trials) was not analyzed, to provide a broad estimate of real-world outcomes, and so we cannot comment upon whether or how antidepressant resistance was associated with clinical outcomes. We were also not able to precisely identify every reason for dropout. Patient demographics are consistent with VA studies, although many races, ethnicities and genders were represented. Future investigations will evaluate clinically important aspects of care, such as impact of varied parameters and medications (including changes thereof), TBI status, durability of effect, and effects of TMS on PTSD symptom domains. Future precision medicine studies (e.g., Williams et al., 2021), using this VA network will provide large-scale insight into clinical biomarkers of treatment response.

Caveats notwithstanding, this is the largest report of TMS in US military veterans and provides a clear indication of the safety and effectiveness of TMS. Greater exposure to TMS (i.e., more treatment sessions) yielded superior MDD outcomes, and TMS was broadly efficacious for PTSD. Comorbid PTSD was not clearly associated with poorer outcomes and as such, TMS can be recommended for this patient population.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We thank all the VA clinical TMS sites and their patients. For full details of the program sites please see the associated website at the Sierra Pacific (VISN 21) MIRECC - MIRECC / CoE ([va.gov](https://www.va.gov)). We would also like to thank Laura Lazzaroni, PhD for statistical support.

GRANT SUPPORT

The VA Clinical TMS Program is supported by the VA Office of Mental Health and Suicide Prevention; VA provided clinical support for the program in terms of both equipment and workload for allocation of staff resources. Effort on this project was supported in part by the VA RR&D Center for Neurorestoration and Neurotechnology at the Providence VA (NSP), NIMH R01 MH120126 & VA I01 CX002088.

REFERENCES

1. Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. *Arch Intern Med*. 2000 11 27;160(21):3252–7. doi: 10.1001/archinte.160.21.3252. PMID: 11088086. [PubMed: 11088086]
2. Ahmadizadeh M-J & Rezaei M Unilateral right and bilateral dorsolateral prefrontal cortex transcranial magnetic stimulation in treatment posttraumatic stress disorder: a randomized controlled study. *Brain Res. Bull.* 140, 334–340 (2018). [PubMed: 29883597]
3. Beam W, Borckardt JJ, Reeves ST, George MS. An efficient and accurate new method for locating the F3 position for prefrontal TMS applications. *Brain Stimul.* 2009 1;2(1):50–4. doi: 10.1016/j.brs.2008.09.006. PMID: 20539835; PMCID: PMC2882797. [PubMed: 20539835]
4. Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. *Lancet*. 2018 4 28;391(10131):1683–1692. doi: 10.1016/S0140-6736(18)30295-2. Epub 2018 Apr 26. Erratum in: *Lancet*. 2018 Jun 23;391(10139):e24. PMID: 29726344. [PubMed: 29726344]


5. Boggio PS et al. Noninvasive brain stimulation with high-frequency and low intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder. *J. Clin. Psychiatry* 71, 992–999 (2010). [PubMed: 20051219]
6. Brunelin J, Jalenques I, Trojak B, Attal J, Szekely D, Gay A, Januel D, Haffen E, Schott-Pethelaz AM, Brault C; STEP Group, Poulet E. The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment-resistant depression: the results from a large multicenter French RCT. *Brain Stimul.* 2014 Nov-Dec;7(6):855–63. doi: 10.1016/j.brs.2014.07.040. Epub 2014 Aug 7. PMID: 25192980. [PubMed: 25192980]
7. Carpenter L, Aaronson S, Hutton TM, Mina M, Pages K, Verdoliva S, West WS, Sackeim H. Comparison of clinical outcomes with two Transcranial Magnetic Stimulation treatment protocols for major depressive disorder. *Brain Stimul.* 2021 Jan-Feb;14(1):173–180. doi: 10.1016/j.brs.2020.12.003. Epub 2020 Dec 17. PMID: 33346068. [PubMed: 33346068]
8. Carpenter LL, Conelea C, Tyrka AR, Welch ES, Greenberg BD, Price LH, Niedzwiecki M, Yip AG, Barnes J, Philip NS. 5 Hz Repetitive transcranial magnetic stimulation for posttraumatic stress disorder comorbid with major depressive disorder. *J Affect Disord.* 2018 8 1;235:414–420. doi: 10.1016/j.jad.2018.04.009. Epub 2018 Apr 5. PMID: 29677606; PMCID: PMC6567988. [PubMed: 29677606]
9. Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. *Depress Anxiety.* 2012 7;29(7):587–96. doi: 10.1002/da.21969. Epub 2012 Jun 11. PMID: 22689344. [PubMed: 22689344]
10. Carrico WT, Georgette G, Madore MR, Kozel FA, George MS, Lindley S, Lovett S, Yoon JH, Yesavage JA. A Clinical Program to Implement Repetitive Transcranial Magnetic Stimulation for Depression in the Department of Veterans Affairs. *Fed Pract.* 2020 6;37(6):276–281. PMID: 32669780; PMCID: PMC7357884. [PubMed: 32669780]
11. Cohen J: *Statistical Power Analysis for the Behavioral Sciences*, 2nd ed. Hillsdale, NJ, Lawrence Erlbaum Associates, 1988
12. Cosmo C, Zandvakili A, Petrosino NJ, Berlow YA, Philip NS. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: Recent Critical Advances in Patient Care. *Curr Treat Options Psychiatry.* 2021 3 11:1–17. doi: 10.1007/s40501-021-00238-y. Epub ahead of print. PMID: 33723500; PMCID: PMC7946620.
13. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry.* 2020 11 4:e203285. doi: 10.1001/jamapsychiatry.2020.3285. Epub ahead of print. PMID: 33146667; PMCID: PMC7643046.
14. Eftekhari A, Ruzek JJ, Crowley JJ, Rosen CS, Greenbaum MA, Karlin BE. Effectiveness of national implementation of prolonged exposure therapy in Veterans Affairs care. *JAMA Psychiatry.* 2013 9;70(9):949–55. doi: 10.1001/jamapsychiatry.2013.36. PMID: 23863892. [PubMed: 23863892]
15. Friedrich MJ. Depression Is the Leading Cause of Disability Around the World. *JAMA.* 2017 4 18;317(15):1517. doi: 10.1001/jama.2017.3826. PMID: 28418490.
16. George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. *Arch Gen Psychiatry.* 2010 5;67(5):507–16. doi: 10.1001/archgenpsychiatry.2010.46. PMID: 20439832. [PubMed: 20439832]
17. George MS. Whither TMS: A One-Trick Pony or the Beginning of a Neuroscientific Revolution? *Am J Psychiatry.* 2019 11 1;176(11):904–910. doi: 10.1176/appi.ajp.2019.19090957. PMID: 31672044; PMCID: PMC7871459. [PubMed: 31672044]
18. Hernandez MJ, Reljic T, Van Trees K, Phillips S, Hashimie J, Bajor L, Yehl J, McKenzie BC, Burke C, Sullivan GA, Kumar A, Sanchez DL, Catalano G, Kozel FA. Impact of Comorbid PTSD on Outcome of Repetitive Transcranial Magnetic Stimulation (TMS) for Veterans With Depression. *J Clin Psychiatry.* 2020 7 7;81(4):19m13152. doi: 10.4088/JCP.19m13152. PMID: 32659874.

19. Herwig U, Fallgatter AJ, Höppner J, Eschweiler GW, Kron M, Hajak G, Padberg F, Naderi-Heiden A, Abler B, Eichhammer P, Grossheinrich N, Hay B, Kammer T, Langguth B, Laske C, Plewnia C, Richter MM, Schulz M, Unterecker S, Zinke A, Spitzer M, Schönfeldt-Lecuona C. Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. *Br J Psychiatry*. 2007 11;191:441–8. doi: 10.1192/bjp.bp.106.034371. PMID: 17978325. [PubMed: 17978325]
20. Isserles M, Tendler A, Roth Y, ... Ressler KJ Deep Transcranial Magnetic Stimulation Combined with Brief Exposure for Post-Traumatic Stress Disorder – A Prospective Multisite Randomized Trial. *Biological Psychiatry* (In press) DOI:10.1016/j.biopsych.2021.04.019
21. Isserles M et al. Effectiveness of deep transcranial magnetic stimulation combined with a brief exposure procedure in post-traumatic stress disorder – a pilot study. *Brain Stimul*. 6, 377–383 (2013). [PubMed: 22921765]
22. Kan RLD, Zhang BBB, Zhang JJQ, Kranz GS. Non-invasive brain stimulation for posttraumatic stress disorder: a systematic review and meta-analysis. *Transl Psychiatry*. 2020 5 28;10(1):168. doi: 10.1038/s41398-020-0851-5. PMID: 32467579; PMCID: PMC7256039. [PubMed: 32467579]
23. Karsen EF, Watts BV, Holtzheimer PE. Review of the effectiveness of transcranial magnetic stimulation for post-traumatic stress disorder. *Brain Stimul*. 2014 Mar-Apr;7(2):151–7. doi: 10.1016/j.brs.2013.10.006. Epub 2013 Oct 31. PMID: 24486424. [PubMed: 24486424]
24. Kozel FA, Hernandez M, Van Trees K, Phillips S, Hashimie J, Weisman M, Obregon D, Sanchez DL, Catalano G, Schultz SK. Clinical repetitive transcranial magnetic stimulation for veterans with major depressive disorder. *Ann Clin Psychiatry*. 2017 11;29(4):242–248. PMID: 29069109. [PubMed: 29069109]
25. Kozel FA, Motes MA, Didehban N, DeLaRosa B, Bass C, Schraufnagel CD, Jones P, Morgan CR, Spence JS, Kraut MA, Hart J Jr. Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial. *J Affect Disord*. 2018 3 15;229:506–514. doi: 10.1016/j.jad.2017.12.046. Epub 2017 Dec 28. PMID: 29351885. [PubMed: 29351885]
26. Kozel FA, Van Trees K, Larson V, Phillips S, Hashimie J, Gadbois B, Johnson S, Gallinati J, Barrett B, Toyinbo P, Weisman M, Centorino M, Gibson CA, Catalano G. One hertz versus ten hertz repetitive TMS treatment of PTSD: A randomized clinical trial. *Psychiatry Res*. 2019 3;273:153–162. doi: 10.1016/j.psychres.2019.01.004. Epub 2019 Jan 3. PMID: 30641346. [PubMed: 30641346]
27. Kroenke K, Spitzer RL, Williams JB, 2001. The PHQ-9: validity of a brief depression severity measure. *J. Gen. Intern. Med*. 16 (9), 606–613. 10.1046/j.1525-1497.2001.016009606.x. [PubMed: 11556941]
28. Leong K, Chan P, Ong L, Zwicker A, Willan S, Lam RW, McGirr A. A Randomized Sham-controlled Trial of 1-Hz and 10-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) of the Right Dorsolateral Prefrontal Cortex in Civilian Post-traumatic Stress Disorder: Un essai randomisé contrôlé simulé de stimulation magnétique transcrânienne répétitive (SMTr) de 1 Hz et 10 Hz du cortex préfrontal dorsolatéral droit dans le trouble de stress post-traumatique chez des civils. *Can J Psychiatry*. 2020 11;65(11):770–778. doi: 10.1177/0706743720923064. Epub 2020 May 7. PMID: 32379487; PMCID: PMC7564694. [PubMed: 32379487]
29. McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA Jr, Stahl S. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. *Am J Psychiatry*. 2021 3 17;appiajp202020081251. doi: 10.1176/appi.ajp.2020.20081251. Epub ahead of print. PMID: 33726522.
30. O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. *Biol Psychiatry*. 2007 12 1;62(11):1208–16. doi: 10.1016/j.biopsych.2007.01.018. Epub 2007 Jun 14. PMID: 17573044. [PubMed: 17573044]

31. Philip NS, Barredo J, Aiken E, Larson V, Jones RN, Shea MT, Greenberg BD, van 't Wout-Frank M. Theta-Burst Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder. *Am J Psychiatry*. 2019 11 1;176(11):939–948. doi: 10.1176/appi.ajp.2019.18101160. Epub 2019 Jun 24. PMID: 31230462; PMCID: PMC6824981. [PubMed: 31230462]
32. Philip NS, Doherty RA, Faucher C, Aiken E, van 't Wout-Frank M. Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder and Major Depression: Comparing Commonly Used Clinical Protocols. *J Trauma Stress*. 2021 5 11. doi: 10.1002/jts.22686. Epub ahead of print. PMID: 33973681.
33. Philip NS, Ridout SJ, Albright SE, Sanchez G, Carpenter LL. 5-Hz Transcranial Magnetic Stimulation for Comorbid Posttraumatic Stress Disorder and Major Depression. *J Trauma Stress*. 2016 2;29(1):93–6. doi: 10.1002/jts.22065. Epub 2016 Jan 7. PMID: 26748883; PMCID: PMC4849266. [PubMed: 26748883]
34. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. *Neuropsychopharmacology* 2006; 31: 1841–53 [PubMed: 16794566]
35. Sackeim HA. Acute Continuation and Maintenance Treatment of Major Depressive Episodes With Transcranial Magnetic Stimulation. *Brain Stimul*. 2016 May-Jun;9(3):313–319. doi: 10.1016/j.brs.2016.03.006. Epub 2016 Mar 11. PMID: 27052475. [PubMed: 27052475]
36. Sackeim HA. Modern Electroconvulsive Therapy: Vastly Improved yet Greatly Underused. *JAMA Psychiatry*. 2017 8 1;74(8):779–780. doi: 10.1001/jamapsychiatry.2017.1670. PMID: 28658461. [PubMed: 28658461]
37. Suicide Among Veterans and Other Americans 2001–2014. 2016, US Department of Veteran Affairs: Washington DC.
38. Watts BV, Landon B, Groft A, Young-Xu Y. A sham controlled study of repetitive transcranial magnetic stimulation for posttraumatic stress disorder. *Brain Stimul*. 2012 1;5(1):38–43. doi: 10.1016/j.brs.2011.02.002. Epub 2011 Mar 3. PMID: 22264669. [PubMed: 22264669]
39. Weathers FW, Blake DD, Schnurr PP, et al.: The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Washington, DC, US Dept of Veterans Affairs, 2013 (<https://www.ptsd.va.gov/professional/assessment/adult-int/caps.asp>)
40. Weathers FW, L BT, Keave TM, Palmieri PA, Marx BP, Schnurr P, 2013a. The PTSD Checklist for DSM-5 (PCL-5). National Center for PTSD. <https://www.ptsd.va.gov/professional/assessment/adult-sr/ptsd-checklist.asp>.
41. Williams LM, Coman JT, Stetz PC, Walker NC, Kozel FA, George MS, Yoon J, Hack LM, Madore MR, Lim KO, Philip NS, Holtzheimer PE. Identifying response and predictive biomarkers for Transcranial magnetic stimulation outcomes: protocol and rationale for a mechanistic study of functional neuroimaging and behavioral biomarkers in veterans with Pharmacoresistant depression. *BMC Psychiatry*. 2021 1 13;21(1):35. doi: 10.1186/s12888-020-03030-z. PMID: 33435926; PMCID: PMC7805238. [PubMed: 33435926]
42. Yesavage JA, Fairchild JK, Mi Z, Biswas K, Davis-Karim A, Phibbs CS, Forman SD, Thase M, Williams LM, Etkin A, O'Hara R, Georgette G, Beale T, Huang GD, Noda A, George MS; VA Cooperative Studies Program Study Team. Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial. *JAMA Psychiatry*. 2018 9 1;75(9):884–893. doi: 10.1001/jamapsychiatry.2018.1483. PMID: 29955803; PMCID: PMC6142912. [PubMed: 29955803]

HIGHLIGHTS


- Largest study of transcranial magnetic stimulation (TMS) of US military veterans
- TMS yielded clinically meaningful reductions in depression and PTSD symptoms.
- Posttraumatic stress disorder did not impact the magnitude of observed improvements.
- Side effects were consistent with the known safety profile of TMS.

**A****Figure 1A.**

Trajectory of MDD and PTSD symptoms across the entire group (n=770).

Bars represent standard error of the mean. The Y-axis represents symptom scores, and X-axis describes week of TMS treatment.

Abbreviations: Pre-Tx, pre-treatment; Post-Tx, post-treatment; PHQ-9, 9-item patient health questionnaire; PCL-5, PTSD checklist for DSM-5




B.

Figure 1B.

Trajectory of MDD and PTSD symptoms in patients who received an adequate dose of at least 30 TMS sessions (n=340).


Bars represent standard error of the mean. The Y-axis represents symptom scores, and X-axis describes week of TMS treatment.

Abbreviations: Pre-Tx, pre-treatment; Post-Tx, post-treatment; PHQ-9, 9-item patient health questionnaire; PCL-5, PTSD checklist for DSM-5

**A****Figure 2A.**

MDD outcomes in patients with and without threshold-level PTSD symptom severity in the entire cohort.

Key: Y-axis represents mean PHQ9 scores, and “PTSD” indicates threshold-level PTSD symptom severity. Error bars represent standard error of the mean.



B

Figure 2B.

MDD outcomes in patients with and without threshold-level PTSD symptom severity in patients who received an adequate dose of at least 30 TMS sessions.

Key: Y-axis represents mean PHQ9 scores, and “PTSD” indicates threshold-level PTSD symptom severity. Error bars represent standard error of the mean.

Table 1.

Demographics and Clinical Characteristics

	Entire Group ¹ (n = 770)	Adequate Dose ¹ (n = 340)
Age (mean, SD)	51.84 (14.11)	53.39 (13.97)
Race		
White	552 (71.6%)	260 (76.1%)
Black	88 (11.4%)	39 (11.5%)
Asian	18 (2.3%)	7 (2.2%)
Multiracial	16 (2.1%)	4 (1.3%)
Other ²	49 (6.5%)	15 (4.4%)
No response	47 (6.1%)	15 (4.5%)
Biological Sex		
Male	592 (76.8%)	269 (79%)
Female	141 (18.4%)	60 (17.8%)
No response	37 (4.8%)	11 (3.2%)
Gender		
Male	394 (51.2%)	163 (47.8%)
Female	105 (13.8%)	48 (14.0%)
Transgender	7 (0.9%)	-
Androgynous	1 (0.1%)	-
Agender	5 (0.6%)	1 (0.3%)
No response	258 (33.5%)	129 (37.9%)
Highest Education Achieved		
Elementary School	5 (0.6%)	2 (0.6%)
High School or GED	72 (9.4%)	22 (6.4%)
Some college, no degree	228 (29.6%)	99 (29%)
Associate degree, vocational program, or certificate	121 (15.7%)	54 (15.9%)
Bachelor's degree	144 (18.7%)	67 (19.7%)
Master's degree	88 (11.4%)	45 (13.1%)
Doctoral degree	20 (2.6%)	6 (1.9%)
No response	92 (11.9%)	46 (13.4%)
Dropout	126 (16.4%)	25 (8%)

	Entire Group ¹ (n = 770)	Adequate Dose ¹ (n = 340)
History of suicide attempts		
Yes	250 (32.5%)	96 (30.6%)
No	425 (55.2%)	177 (56.4%)
No response	95 (12.3%)	41 (13.3%)
History of psychiatric hospitalizations		
Yes	361 (46.9%)	134 (42.7%)
No	310 (40.3%)	139 (44.3%)
No response	99 (12.9%)	41 (13.1%)
Self-reported co-morbidities		
PTSD	379 (49.2%)	149 (47.5%)
Substance Use Disorder	75 (9.7%)	26 (8.3%)
Alcohol Use Disorder	100 (13.0%)	40 (12.7%)
Anxiety Spectrum Disorders	259 (33.6%)	105 (33.4%)
Obsessive Compulsive Disorder	28 (3.6%)	16 (5.1%)
Bipolar Disorder	90 (11.7%)	33 (10.5%)
Self-reported prior traumatic brain injury		
No	304 (39.5%)	150 (44.1%)
Yes	313 (40.6%)	165 (48.5%)
Unknown or Missing	153 (19.9%)	27 (7.4%)

¹ Note that numbers may not equal 100% based on patient responses. “Entire Group” indicates those patients that received a baseline assessment and at least one TMS session, and “Adequate Dose” indicates those patients who received at least thirty sessions of TMS therapy.

² Includes: Asian Indian; American Indian; Native Alaskan; Pacific Islander; Middle Eastern.

Table 2.**TMS Approaches**

TMS Frequency and Target	n (%)
10 Hz left DLPFC	595 (69.8%)
5 Hz left DLPFC	70 (8.2%)
iTBS left DLPFC (600 pulses)	59 (7.1%)
1 Hz right DLPFC	24 (2.8%)
18 Hz dTMS	67 (7.9%)
1 Hz dTMS	12 (1.4%)
Other	24 (2.8%)

Abbreviations are as follows: Hz = hertz; DLPFC = dorsolateral prefrontal cortex; iTBS = intermittent theta burst; dTMS = deep transcranial magnetic stimulation.

FDA cleared TMS parameters included 10Hz for Magstim, Neuronetics or Magventure systems for 4s, 11–26s intertrain interval (ITI), 3000 pulses per session; Brainsway devices using 18Hz for 2s, 20s ITI, 1980 pulses; and intermittent theta burst delivering 50Hz triplets at 5Hz, 2s stimulation with 8s ITI, 600 pulses).